Companies · Biotechnology

Redwood Bioscience Inc

EMERYVILLE · Biotechnology

Diligence memoA one-page analyst read on Redwood Bioscience Inc — recommendation, valuation, rhythm, risks.
$11.9M
Total raised · real
4
Rounds
0.3×
Latest step-up
Top 42%
Sector rank · raised
Series A
Latest stage · inferred · Thu Jan 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Redwood Bioscience Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.57× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.
Dormant
  • Last raise 12.5 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Redwood Bioscience Inc is one of 4291 Biotechnology companies tracked from EMERYVILLE. By capital raised it ranks mid-pack (ahead of 59% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2008-09-30 Raised $450K (real) Modeled valuation $25M (est)$450K$25MPre-Seed2008Pre-Seed · 2010-03-03 Raised $300K (real) Modeled valuation $17M (est)$300K$17MPre-Seed2010Series A · 2013-04-08 Raised $8.6M (real) Modeled valuation $313M (est)$8.6M$313MSeries A2013Series A · 2014-01-16 Raised $2.5M (real) Modeled valuation $90M (est)$2.5M$90MSeries A2014+$300K+$8.6M+$2.5MCumulative $12M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$450K · 2008
Pre-Seed extension$300K · 2010
Series A$8.6M · 2013no Seed on file
Series A extension$2.5M · 2014

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$90.4M
Base estimate est.
$2.7M
Conservative case
$491.4M
Upside case
$11.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $24.8M · 2008-09-302008Pre-Seed · modeled $16.6M · 2010-03-03Series A · modeled $312.6M · 2013-04-08Series A · modeled $90.4M · 2014-01-162014
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
12.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
21 mo
Avg between rounds
$2.2M/yr
Capital velocity
17.8 yr
On record since
2008
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.7× above median
This company$11.9M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.5× of median
This company$2.5M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.4× above median
This company$90.4M
Sector median$64.2M

Raised more than 59% of sector peers (real $). Modeled value above 57% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #81 of 111.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Dnanexus, Inc. · Series A Raised $31.6M · modeled $542.3M (est)Foresight Biotherapeutics, Inc. · Series A Raised $17.0M · modeled $542.3M (est)AuraSense Therapeutics, LLC · Series A Raised $33.6M · modeled $535.0M (est)Zyomyx Inc · Series A Raised $15.2M · modeled $514.1M (est)Thrasos Innovation Inc. · Series A Raised $14.0M · modeled $506.1M (est)Champions Oncology, Inc. · Series A Raised $36.8M · modeled $506.1M (est)Merganser Biotech, Inc. · Series A Raised $21.1M · modeled $473.5M (est)Progenics Pharmaceuticals Inc · Series A Raised $12.9M · modeled $467.2M (est)GeneWeave Biosciences, Inc. · Series A Raised $36.3M · modeled $441.0M (est)Aeglea BioTherapeutics Holdings, LLC · Series A Raised $15.8M · modeled $387.1M (est)Hydra Biosciences Inc · Series A Raised $10.5M · modeled $379.9M (est)Brainstorm Cell Therapeutics Inc. · Series A Raised $12.3M · modeled $379.6M (est)Redwood Bioscience Inc (this company) Raised $11.9M · modeled $90.4M (est)Redwood Bioscience Inc
CompanyStageRaised · realValue · estvs peer med.
Dnanexus, Inc.Series A$31.6M$542.3M3.41×
Foresight Biotherapeutics, Inc.Series A$17.0M$542.3M3.41×
AuraSense Therapeutics, LLCSeries A$33.6M$535.0M3.36×
Zyomyx IncSeries A$15.2M$514.1M3.23×
Thrasos Innovation Inc.Series A$14.0M$506.1M3.18×
Champions Oncology, Inc.Series A$36.8M$506.1M3.18×
Merganser Biotech, Inc.Series A$21.1M$473.5M2.98×
Progenics Pharmaceuticals IncSeries A$12.9M$467.2M2.94×
GeneWeave Biosciences, Inc.Series A$36.3M$441.0M2.77×
Aeglea BioTherapeutics Holdings, LLCSeries A$15.8M$387.1M2.43×
Hydra Biosciences IncSeries A$10.5M$379.9M2.39×
Brainstorm Cell Therapeutics Inc.Series A$12.3M$379.6M2.39×
Redwood Bioscience Inc this companySeries A$11.9M$90.4M0.57×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$450K2008-09-30$2.5M$24.8M90%
Pre-Seed$300K2010-03-03$1.7M$16.6M90%
Series A$8.6M2013-04-08$39.3M$312.6M90%
Series A$2.5M2014-01-16$11.4M$90.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$450K2008-09-30
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$300K2010-03-03
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
  3. Series A$8.6M2013-04-08
    • Raised again after 37 mo — slower than the ~14 mo sector norm.
    • Round 28.8× larger than the prior — scaling up.
  4. Series A$2.5M2014-01-16
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 3.5× smaller than the prior — bridge or down round.
Intelligence
2015 ~Q4
Modeled next raise · ~21mo cadence
$2.5M
Modeled next size est.range $2.5M$4.0M
0.3×
Last step-up
$2.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
MICHAEL BLANK4 other2013-04
KAREN BOEZI2 other2013-04
J GORDON FOULKES1 other2013-04
Michael M. Blank1 other2014-01
BARRY LITTLEJOHNS2013-04
BARRY M LITTLEJOHNS2014-01
Carolyn Ian Bertozzi2008-09
DAVID GORDON RABUKA2013-04
David Ian Rabuka2008-09
EDWARD GORDON MCCRACKEN2013-04
Karen Ian Boezi2008-09
KAREN M BOEZI2014-01
Michael Ian Blank2008-09
Paul Ian Socolow2008-09
Registry & provenance

Redwood Bioscience Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1432333
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Zebra Biologics, Inc.BiotechnologySeries A$12.0M$108.5Msame sector · same stage
Automera US Inc.BiotechnologySeries A$12.2M$95.1Msame sector · same stage
LunaPBC, Inc.BiotechnologySeries A$11.4M$90.7Msame sector · same stage
Pebble Labs Inc.BiotechnologySeries A$12.5M$108.5Msame sector · same stage
Everist Genomics, Inc.BiotechnologySeries A$12.5M$110.7Msame sector · same stage
Total Joint Orthopedics, Inc.BiotechnologySeries A$12.6M$88.8Msame sector · same stage
BeneVir Biopharm, Inc.BiotechnologySeries A$11.0M$72.3Msame sector · same stage
JW Celtics Investment Corp.BiotechnologySeries A$11.0M$100.1Msame sector · same stage
Frequently asked
How much funding has Redwood Bioscience Inc raised?
Redwood Bioscience Inc has raised approximately $11.9M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Redwood Bioscience Inc's estimated valuation?
Provath's modeled valuation for Redwood Bioscience Inc is approximately $90.4M (modeled range $2.7M–$491.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Redwood Bioscience Inc at?
Redwood Bioscience Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Jan 16.
What does Redwood Bioscience Inc do and where is it based?
Redwood Bioscience Inc operates in the Biotechnology sector, based in EMERYVILLE.
Explore related

See where Redwood Bioscience Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Redwood Bioscience Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.